Holen Sie sich die Stockscreener-App
47.88
7.53%
3.42
Schlusskurs vom Vortag:
$44.46
Offen:
$44.54
24-Stunden-Volumen:
25.89M
Relative Volume:
0.71
Marktkapitalisierung:
$10.42B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
69.39
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
+8.36%
1M Leistung:
-24.53%
6M Leistung:
+18.08%
1J Leistung:
+227.24%
1-Tages-Spanne:
$44.30
$47.91
1-Wochen-Bereich:
$40.78
$47.87
52-Wochen-Spanne:
$13.47
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Vergleichen Sie HIMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
47.88 | 9.39B | 1.78B | 164.40M | 236.51M | 0.69 |
|
PG
Procter Gamble Co
|
159.15 | 370.07B | 84.28B | 16.07B | 14.05B | 6.51 |
|
UL
Unilever Plc Adr
|
64.53 | 155.79B | 64.99B | 6.71B | 6.53B | 2.4495 |
|
CL
Colgate Palmolive Co
|
83.39 | 68.21B | 20.00B | 3.05B | 3.37B | 3.56 |
|
KMB
Kimberly Clark Corp
|
128.82 | 42.75B | 18.88B | 2.38B | 2.10B | 7.26 |
|
KVUE
Kenvue Inc
|
20.41 | 39.88B | 15.14B | 1.42B | 1.63B | 0.74 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Eli Lillys 036 Gains Overshadowed by 3075 Volume Drop as Court Dismisses Lawsuit Stock Ranks 33rd in Market Activity Amid Hims Surge - AInvest
Strategic Capital Moves in Disruptive Consumer & Mobility Sectors: Lyft, Hims & Hers, and Constellation Brands - AInvest
Noteworthy Wednesday Option Activity: HIMS, UNH, SMMT - Nasdaq
Lyft convertible notes, Hims & Hers surges, Constellation Brands - Yahoo Finance
Hims & Hers Health Stock (HIMS) Opinions on Telehealth Innovation and Recent Setbacks - Quiver Quantitative
Hims & Hers gains after court rejects Eli Lilly’s case against Willow - Yahoo Finance
Hims & Hers Health Set to Meet Revenue Projections Amid Growing Confidence - StocksToTrade
Hims & Hers Sees Revenue Growth Amid Deutsche Bank’s Optimistic Outlook - timothysykes.com
Hers Health Inc.Weekly Market Report & Community Consensus Picks - Newser
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock - Yahoo Finance
Hers Health Inc. in sector analysis2025 Institutional Moves & Long-Term Safe Investment Ideas - Newser
HIMS' Personalized Wellness Platform Expands Preventive Care Access - sharewise.com
Hers Health Inc. holdersBond Market & Long-Term Growth Portfolio Plans - Newser
Hers Health Inc. reversing from oversold territoryLayoff News & Accurate Buy Signal Notifications - Newser
Hims & Hers Health: Still Undervalued (NYSE:HIMS) - Seeking Alpha
Hers Health Inc. stock trend forecastRisk Management & Reliable Volume Spike Trade Alerts - Newser
Hers Health Inc. bounce back from current support2025 Price Targets & AI Enhanced Trading Signals - Newser
Insider Moves: Datadog, Hims & Hers, Opendoor, Texas Instruments, Vertiv - TipRanks
Hers Health Inc.’s reversalGap Down & Stock Timing and Entry Methods - Newser
Hims & Hers: The Dominant Health Platform Of The Future (NYSE:HIMS) - Seeking Alpha
Real time social sentiment graph for HIMSNew Guidance & Safe Entry Trade Reports - Newser
Hers Health Inc. stock entering bullish territoryTrade Exit Report & Growth Focused Entry Reports - Newser
Hims & Hers Climbs to 102nd in Market Activity With $790M Volume as Insider Sales and Mixed Earnings Spark Doubts - AInvest
Hims & Hers Health Insider Selling: Signal of Distrust or Strategic Rebalancing? - AInvest
Hers Health Inc. in the next 30 daysPortfolio Growth Summary & Weekly Top Gainers Alerts - Newser
HIMS vs. AMWL: Which Stock Has the Stronger Global Growth Strategy? - The Globe and Mail
Hims & Hers Health Stock Plunges 2.95% as Trading Volume Falls 32% to $890M and Drops to 67th in Activity - AInvest
Hims & Hers’ growth prospects clouded by Novo dispute and regulatory scrutiny - S&P Global
HIMS & HERS ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Hims & Hers Scales Growth Through Subscriptions and Care Expansion - sharewise.com
Hims & Hers Health Is Looking to Cash In on This Novo Nordisk Blunder - ca.finance.yahoo.com
Hims & Hers Health Clears Key Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily
Hers Health Inc. stock performanceQuarterly Trade Review & Daily Growth Stock Investment Tips - Newser
Hims & Hers Stocks: Join the Pharma Boom? - StocksToTrade
Hims & Hers Health Stock (HIMS) Opinions on Telehealth Disruption and Recent Challenges - Quiver Quantitative
Hims & Hers Health Surges 5.15% on Intraday Rally—What’s Fueling the Momentum? - AInvest
Hims & Hers' Resilience Amid GLP-1 Market Shifts: Short-Term Volatility vs. Long-Term Personalized Care Positioning - AInvest
Hims & Hers Health, Inc. Class Action: Levi & Korsinsky - GlobeNewswire
Hims & Hers: Navigating Short-Sellers and Regulatory Storms in the DTC Healthcare Sector - AInvest
Levi & Korsinsky Helps Shareholders SueWallSt After Hims & Hers Health, Inc. Stock Drops - Stockhouse
Hims & Hers Health: Navigating Regulatory Storms and Rebuilding a Growth Narrative - AInvest
Hims & Hers: A Case Study in Governance and Partnership Risks in the Digital Health Sector - AInvest
Rocket, Oscar, Hims & Hers: Short Sellers Are Playing With Fire - Benzinga
Did You Lose Money on Hims & Hers Health, Inc. (HIMS)? Levi & Korsinsky Urges Investors to Act Before August 25, 2025 - ACCESS Newswire
Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers - Benzinga
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
DEADLINE ALERT for HIMS, IRBT, and CNC: The Law Offices of - GlobeNewswire
Hims & Hers Health, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before August 25, 2025 to Discuss Your RightsHIMS - PR Newswire
Is Regulatory Scrutiny and Novo Nordisk Partnership Loss Changing the Investment Case for Hims & Hers Health (HIMS)? - Yahoo Finance
Top 3 US Digital Health Stocks That are Leading the Healthcare Revolution - The Smart Investor
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.05%
3.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):